Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Yuval Gabay"'
Autor:
Ettai Markovits, David Soong, Becky Arbiv, Alon Groisman, Maya Lipinsky, Yoni Yedidia, Yoad Cohen, Yuval Gabay, Yuval Shachaf, Eyal Oren, Roman Gluskin, Ido Weiss, Hisham Hamadeh, Kate Sasser, Gali Golan, Brandon Higgs, Suzana Couto, Ori Zelichov
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e37d01d51e9e4347e2dea62c0d520a9d
https://doi.org/10.1136/jitc-2022-sitc2022.1289
https://doi.org/10.1136/jitc-2022-sitc2022.1289
Autor:
Anna Pokorska-Bocci, Sandrine Micallef, Mariola Dymkowska, Yuval Gabay, Roman Gluskin, Avi Laniado, Efrat Dicker Sagy, Amit Bart, Tomer Dicker, Ifat Rotbein, Albert Achtenberg, Ori Zelichov
Publikováno v:
Journal of Clinical Oncology. 40:e19565-e19565
e19565 Background: DLBCL is the most common type of Non-Hodgkin’s lymphoma, accounting for 30-40% of cases. Despite improvements in response and survival with standard of care treatment, up to 40% of patients have relapsed and/or refractory (R/R) d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6da3985e0d2d9d9cfd5824af9dbb2cf9
https://doi.org/10.1200/jco.2022.40.16_suppl.e19565
https://doi.org/10.1200/jco.2022.40.16_suppl.e19565
Autor:
Roman Gluskin, Avi Laniado, Chen Sade, Jair Bar, Efrat Ofek, Yuval Gabay, Meora Feinmesser, Ori Zelichov, Alon Groisman, Albert Achtenberg, Damien Urban, Alona Zer, Iris Barshack, Willy Polychenko, Chen Mayer
Publikováno v:
Journal of Clinical Oncology. 39:9045-9045
9045 Background: Immune checkpoint inhibitors (ICI) have become the standard treatment for metastatic NSCLC, although only a small proportion of patients derive durable benefit. PDL1 expression is the only approved biomarker to select NSCLC patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df1e39d224eb9d5cc92c0a3cc1659063
https://doi.org/10.1200/jco.2021.39.15_suppl.9045
https://doi.org/10.1200/jco.2021.39.15_suppl.9045
Autor:
Iris Barshack, Ady Yosepovich, Dana Morzaev-Sulzbach, Yossef Molchanov, Roman Gluskin, Kira Deborah Nahum Sacks, Ori Zelichov, Yuval Gabay, Maya Dadiani, Yuval Shachaf, Alon Griosman, Albert Achtenberg, Amir Luchtenstein, Einav Nili Gal-Yam, Noa Ben-Baruch, Alexander J. Lazar, Kathrina Alexander, Nora Balint-Lahat, Chen Mayer, Shahar Ish-Shalom
Publikováno v:
Journal of Clinical Oncology. 38:530-530
530 Background: Tumor-infiltrating lymphocytes in breast cancer have emerged as both a prognostic and a potentially predictive immunotherapy biomarker. Advancements in artificial intelligence can extract pathology-based spatial immune fingerprints fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f638314e81d7cd037964940b09e5776
https://doi.org/10.1200/jco.2020.38.15_suppl.530
https://doi.org/10.1200/jco.2020.38.15_suppl.530